Arduino has become one of the key building blocks of the open hardware movement. Arduino, the platform, is designed to be modular, affordable, and easy for virtually anyone to use. The company behind ...

Scanners for loose papers have become so commonplace that almost every printer includes one, but book scanners have remained frustratingly rare for non-librarians and archivists. [Brad Mattson] had ...

R1 Therapeutics is debuting with an oversubscribed $77.5 million series A financing aimed at advancing its first-in-class therapy for chronic kidney disease (CKD) patients on dialysis with high ...

Financing and global licensing deal to accelerate phase 2b development of AP306 R1 Therapeutics has launched with an oversubscribed $77.5 million Series A financing and an exclusive global licence to ...

Weeping Peninsula (South Limgrave) - Dungeons, Points of Interest, and Secrets East Liurnia - Dungeons, Points of Interest, and Secrets North Liurnia - Dungeons, Points of Interest, and Secrets West ...

Rivian is gearing up to launch the highly anticipated R2 on March 12, but it looks like they’re also planning to trim the R1 lineup. This is unfortunate, but the company sent out a rather ominous ...

This library is fully compatible with other ACAN libraries, it uses a very similar API and the same CANFDMessage and CANMessageclasses for handling messages. The driver supports many bit rates, as ...

Forbes contributors publish independent expert analyses and insights. Sasha Lekach covers electric vehicles and vehicle technology. Rivian finally gave more details on its next, smaller all-electric ...

REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE)-- R1 Therapeutics, Inc (“R1”), a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with ...

This is an STM32CubeIDE workspace with a single project for Arduino GIGA R1 Wifi initialization. Using this project, you can use the GIGA board without the Arduino environment. Clone the repo to your ...

March 17 (Reuters) - R1 Therapeutics said on Tuesday it had launched operations with a $77.5 million Series A funding round and an exclusive license to develop and commercialize a drug for high ...